<?xml version="1.0" encoding="UTF-8"?>
<p>Hypertensive patients were recruited to participate in this placebo-controlled study. Patients with stage 1 systemic arterial hypertension (mild hypertension) were included. This degree of hypertension is characterized by levels of systolic blood pressure between 140 and 159 mmHg and/or diastolic blood pressure between 90 and 99 mmHg [
 <xref rid="B15-nutrients-13-00798" ref-type="bibr">15</xref>]. Patients were evaluated by 24-hour blood pressure monitoring to confirm the diagnosis of hypertension and for follow-up during the experimental period. The study included patients of both genders with a minimum age of 20 and a maximum age of 64 years. Patients with diabetes mellitus or under pharmacological treatment for hypertension were not included. The study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki and approved by the Research Ethics Committee of the University Hospital of the Federal University of Paraiba, Brazil (protocol nº 1.523.128/2016). Written informed consent was obtained from all volunteers prior to participation. In addition, this clinical protocol was approved in the Brazilian Registry of Clinical Trials (nº RBR-5s9bhc).
</p>
